MedTrace Logo

A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients

NCT01328093 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 678

Last updated 2022-09-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether weight gain will be significantly less in LY2140023 than aripiprazole in patients with schizophrenia.

Conditions

Interventions

DRUG

LY2140023

Administered orally

DRUG

Aripiprazole

Administered orally

Sponsors & Collaborators

  • Denovo Biopharma LLC

    lead INDUSTRY

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States
  • Austria
  • Belgium
  • France
  • Germany
  • Poland
  • Puerto Rico
  • Romania
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01328093 on ClinicalTrials.gov